Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BCLI 
Brainstorm Cell Therapeutics Inc (BCLI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/09/2025: BCLI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20.68
1 Year Target Price $20.68
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.58% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.95M USD | Price to earnings Ratio - | 1Y Target Price 20.68 |
Price to earnings Ratio - | 1Y Target Price 20.68 | ||
Volume (30-day avg) 1 | Beta 0.29 | 52 Weeks Range 0.52 - 2.50 | Updated Date 10/16/2025 |
52 Weeks Range 0.52 - 2.50 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -180.31% | Return on Equity (TTM) -1121.9% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7223798 | Price to Sales(TTM) - |
Enterprise Value 7223798 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.7 | Shares Outstanding 10376109 | Shares Floating 9405216 |
Shares Outstanding 10376109 | Shares Floating 9405216 | ||
Percent Insiders 11.92 | Percent Institutions 3.79 |
Upturn AI SWOT
Brainstorm Cell Therapeutics Inc
Company Overview
History and Background
Brainstorm Cell Therapeutics Inc. was founded in 2003. It is a biotechnology company focused on developing adult stem cell therapies for neurodegenerative diseases.
Core Business Areas
- NurOwn: Development and clinical trials of NurOwn (MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis (MS).
Leadership and Structure
The leadership team includes Chaim Lebovits (CEO). The organizational structure is typical of a biotechnology company, with departments focused on research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- NurOwn: NurOwn is Brainstorm's lead product candidate, an autologous cell therapy for ALS and MS. While awaiting potential regulatory approval, it does not yet have revenue or market share. Competitors are companies developing other ALS and MS treatments, such as Biogen (BIIB) and Amylyx Pharmaceuticals (AMLX).
Market Dynamics
Industry Overview
The biotechnology industry is focused on developing innovative therapies for unmet medical needs. There is significant competition and high regulatory hurdles.
Positioning
Brainstorm is positioned as a company specializing in cell therapies for neurodegenerative diseases. Its competitive advantage lies in its NurOwn technology, but this requires further clinical validation and regulatory approval.
Total Addressable Market (TAM)
The total addressable market for ALS and MS treatments is substantial, estimated to be billions of dollars. Brainstorm's positioning depends on the approval and adoption of NurOwn.
Upturn SWOT Analysis
Strengths
- Proprietary NurOwn technology
- Focus on unmet medical needs in neurodegenerative diseases
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial results and regulatory approval
- No currently marketed products
Opportunities
- Potential for breakthrough therapies in ALS and MS
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other companies with more advanced or promising therapies
- Financing risk
Competitors and Market Share
Key Competitors
- BIIB
- AMLX
- ITCI
Competitive Landscape
Brainstorm faces intense competition from established pharmaceutical companies with greater resources and approved therapies. Its competitive advantage depends on NurOwn demonstrating superior efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: There has been no revenue growth due to the absence of marketed products.
Future Projections: Future growth is entirely dependent on the successful commercialization of NurOwn or other pipeline products. Analyst projections vary depending on their assessment of clinical and regulatory prospects.
Recent Initiatives: Recent initiatives include ongoing clinical trials of NurOwn and efforts to secure regulatory approval for ALS.
Summary
Brainstorm Cell Therapeutics is a high-risk, high-reward biotechnology company focused on developing cell therapies for neurodegenerative diseases. The company's future is heavily reliant on the success of NurOwn's clinical trials and regulatory approval, as it has no other marketed products. It needs to secure additional funding to support ongoing operations. Brainstorm faces significant competition and regulatory hurdles in its path to potential commercial success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Press releases
- Analyst reports
- Company website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be outdated. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Brainstorm Cell Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2003-08-28 | President & CEO Mr. Chaim Lebovits | ||
Sector Healthcare | Industry Biotechnology | Full time employees 29 | Website https://www.brainstorm-cell.com |
Full time employees 29 | Website https://www.brainstorm-cell.com | ||
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.